SynCore Biotechnology Co (杏國新藥) is planning an interim analysis of its pancreatic cancer treatment, SB05PC, later this month to determine the drug’s safety and efficacy.
The company is conducting a phase III trial for the drug in Taiwan, the US, France, Hungary, South Korea, Russia and Israel, SynCore general manager Su Muh-hwan (蘇慕寰) told the Taipei Times on Thursday by telephone.
The company aims to use the drug as a second-line treatment in combination with gemcitabine, a chemotherapy medication, for people who do not respond to first-line medicine Folfirinox, a combination of leucovorin, fluorouracil, irinotecan and oxaliplatin.
Participants in the phase III trial are randomly separated into two groups, with one injected with only gemcitabine and the other tested with a combination of gemcitabine and SB05PC, Su said.
As SB05PC is designed to prolong a person’s life, SynCore cannot enter into interim analysis of the drug until half of enrolled participants pass away, he said.
Now that 101 of the 200 participants have died, SynCore can collect data and conduct an interim analysis to evaluate if people survive longer than those who have not taken the drug, he said.
During the phase II trial, participants who took SB05PC and gemcitabine had an average overall survival period of nine months, compared with 7.4 months for those who only received gemcitabine, Su said.
Overall survival is the length of time from the start of treatment to a person’s death, he added.
As for the drug’s progression-free survival (PFS) — the length of time during and after treatment that the disease does not get worse — participants who took SB05PC and gemcitabine had an average PFS period of 4.9 months, compared with 3.5 months for those only taking gemcitabine, he said.
SynCore had planned to enroll 218 participants, but the US Food and Drug Administration has approved adjusting that number based on the outcome of the interim analysis, Su said.
The company plans to end enrollment for the phase III trial by the end of this year and complete the trial by the end of next year on the expectation that participants would survive from seven to nine months, he said.
If everything goes smoothly, SynCore plans to apply to the US regulator for marketing approval of the drug in 2022, he added.
SynCore in February delayed its original plan to begin another phase III trial of SB05PC in China as many patients could not go to hospitals due to a lockdown amid a COVID-19 outbreak.
Su said that the firm plans to delay the clinical trial to August.
NEW IDENTITY: Known for its software, India has expanded into hardware, with its semiconductor industry growing from US$38bn in 2023 to US$45bn to US$50bn India on Saturday inaugurated its first semiconductor assembly and test facility, a milestone in the government’s push to reduce dependence on foreign chipmakers and stake a claim in a sector dominated by China. Indian Prime Minister Narendra Modi opened US firm Micron Technology Inc’s semiconductor assembly, test and packaging unit in his home state of Gujarat, hailing the “dawn of a new era” for India’s technology ambitions. “When young Indians look back in the future, they will see this decade as the turning point in our tech future,” Modi told the event, which was broadcast on his YouTube channel. The plant would convert
‘SEISMIC SHIFT’: The researcher forecast there would be about 1.1 billion mobile shipments this year, down from 1.26 billion the prior year and erasing years of gains The global smartphone market is expected to contract 12.9 percent this year due to the unprecedented memorychip shortage, marking “a crisis like no other,” researcher International Data Corp (IDC) said. The new forecast, a dramatic revision down from earlier estimates, gives the latest accounting of the ongoing memory crunch that is affecting every corner of the electronics industry. The demand for advanced memory to power artificial intelligence (AI) tasks has drained global supply until well into next year and jeopardizes the business model of many smartphone makers. IDC forecast about 1.1 billion mobile shipments this year, down from 1.26 billion the prior
People stand in a Pokemon store in Tokyo on Thursday. One of the world highest-grossing franchises is celebrated its 30th anniversary yesterday.
Zimbabwe’s ban on raw lithium exports is forcing Chinese miners to rethink their strategy, speeding up plans to process the metal locally instead of shipping it to China’s vast rechargeable battery industry. The country is Africa’s largest lithium producer and has one of the world’s largest reserves, according to the US Geological Survey (USGS). Zimbabwe already banned the export of lithium ore in 2022 and last year announced it would halt exports of lithium concentrates from January next year. However, on Wednesday it imposed the ban with immediate effect, leaving unclear what the lithium mining sector would do in the
RSS